IL245281A0 - Methods and preparations for the treatment of cancer - Google Patents

Methods and preparations for the treatment of cancer

Info

Publication number
IL245281A0
IL245281A0 IL245281A IL24528116A IL245281A0 IL 245281 A0 IL245281 A0 IL 245281A0 IL 245281 A IL245281 A IL 245281A IL 24528116 A IL24528116 A IL 24528116A IL 245281 A0 IL245281 A0 IL 245281A0
Authority
IL
Israel
Prior art keywords
compositions
methods
treating cancer
cancer
treating
Prior art date
Application number
IL245281A
Other languages
English (en)
Hebrew (he)
Inventor
Jeffrey A Toretsky
Aykut Uren
Original Assignee
Univ Georgetown
Jeffrey A Toretsky
Aykut Uren
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Georgetown, Jeffrey A Toretsky, Aykut Uren filed Critical Univ Georgetown
Publication of IL245281A0 publication Critical patent/IL245281A0/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40Cyclodextrins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/30Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32Oxygen atoms
    • C07D209/38Oxygen atoms in positions 2 and 3, e.g. isatin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL245281A 2013-10-24 2016-04-21 Methods and preparations for the treatment of cancer IL245281A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361895308P 2013-10-24 2013-10-24
PCT/US2014/061418 WO2015061229A1 (en) 2013-10-24 2014-10-20 Methods and compositions for treating cancer

Publications (1)

Publication Number Publication Date
IL245281A0 true IL245281A0 (en) 2016-06-30

Family

ID=52993423

Family Applications (1)

Application Number Title Priority Date Filing Date
IL245281A IL245281A0 (en) 2013-10-24 2016-04-21 Methods and preparations for the treatment of cancer

Country Status (11)

Country Link
US (2) US9511050B2 (OSRAM)
EP (1) EP3060207A4 (OSRAM)
JP (1) JP6389884B2 (OSRAM)
KR (1) KR20160065986A (OSRAM)
CN (1) CN105848654B (OSRAM)
AU (1) AU2014340398A1 (OSRAM)
CA (1) CA2927148A1 (OSRAM)
IL (1) IL245281A0 (OSRAM)
MX (1) MX2016004678A (OSRAM)
RU (1) RU2016114498A (OSRAM)
WO (1) WO2015061229A1 (OSRAM)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8232310B2 (en) * 2006-12-29 2012-07-31 Georgetown University Targeting of EWS-FLI1 as anti-tumor therapy
RS53350B (sr) 2008-09-22 2014-10-31 Array Biopharma, Inc. Supstituisana jedinjenja imidazo[1,2-b]piridazina kao inhibitori trk kinaze
EP2350071B1 (en) 2008-10-22 2014-01-08 Array Biopharma, Inc. SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS
AR077468A1 (es) 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
PL3205654T3 (pl) 2010-05-20 2019-08-30 Array Biopharma, Inc. Związki makrocykliczne jako inhibitory kinazy TRK
EP2836481B1 (en) 2012-04-12 2018-12-26 Georgetown University Compounds and compositions for treating ewings sarcoma family of tumors
JP6389884B2 (ja) * 2013-10-24 2018-09-12 ジョージタウン・ユニバーシティGeorgetown University 癌を治療するための方法及び組成物
NZ730585A (en) 2014-10-09 2018-08-31 Oncternal Therapeutics Inc Indolinone compounds and uses thereof
CN107428760B (zh) 2014-11-16 2021-04-27 阵列生物制药公司 (s)-n-(5-((r)-2-(2,5-二氟苯基)-吡咯烷-1-基)-吡唑并[1,5-a]嘧啶-3-基)-3-羟基吡咯烷-1-甲酰胺硫酸氢盐的晶型
KR102277538B1 (ko) * 2015-06-08 2021-07-14 주식회사 대웅제약 신규한 헤테로 고리 화합물, 이의 제조 방법 및 이를 포함하는 약학적 조성물
BR112018008357A2 (en) 2015-10-26 2018-11-27 Loxo Oncology, Inc. dot mutations in trk inhibitor resistant cancer and related methods
EP3795563B1 (en) 2016-03-31 2024-07-17 Oncternal Therapeutics, Inc. Indoline analogs and uses thereof
US10045991B2 (en) 2016-04-04 2018-08-14 Loxo Oncology, Inc. Methods of treating pediatric cancers
FI3439662T3 (fi) 2016-04-04 2024-09-04 Loxo Oncology Inc (s)-n-(5-((r)-2-(2,5-difluorifenyyli)pyrrolidin-1-yyli)pyratsolo[1,5-a]pyrimidin-3-yyli)-3-hydroksipyrrolidiini-1-karboksamidin nesteformulaatioita
HRP20201984T1 (hr) 2016-05-18 2021-04-16 Loxo Oncology, Inc. Priprema (s)-n-(5-((r)-2-(2,5-difluorofenil)pirolidin-1-il)pirazolo[1,5-a]pirimidin-3-il)-3-hidroksipirolidin-1-karboksamida
US10613088B2 (en) * 2016-06-12 2020-04-07 Mohammad Abdolahad Method and system for metastasis diagnosis and prognosis
US10761081B2 (en) * 2016-06-12 2020-09-01 Mohammad Abdolahad Method and system for metastasis diagnosis and prognosis
MX395539B (es) 2016-07-29 2025-03-25 Oncternal Therapeutics Inc Usos de compuestos de indolinona
JOP20190092A1 (ar) 2016-10-26 2019-04-25 Array Biopharma Inc عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها
AU2018229294B2 (en) * 2017-02-28 2024-06-13 Exact Sciences Corporation Detecting prostate cancer
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
CN110845389A (zh) * 2019-10-17 2020-02-28 袁健 一种新型i型拓扑异构酶抑制剂
CN114057626B (zh) * 2021-12-07 2023-06-30 山东第一医科大学(山东省医学科学院) 一种吲哚-2,3-二酮的衍生物和制备方法、抑制recql4特异性表达的抗肝癌药物
WO2026009227A1 (en) 2024-07-04 2026-01-08 Yeda Research And Development Co. Ltd. Compositions for downregulating zeb2 in macrophages and uses thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1288436C (en) 1983-07-22 1991-09-03 David Paul Hesson Phenylquinolinecarboxylic acids and derivatives as antitumor agents
DE69922997T2 (de) * 1998-12-04 2005-12-15 Neurosearch A/S Verwendung von isatinderivaten als ionenkanalaktivierende mittel
CN1155572C (zh) 2001-01-19 2004-06-30 中国人民解放军军事医学科学院毒物药物研究所 吲哚类衍生物及其抗肿瘤用途
US20030157486A1 (en) 2001-06-21 2003-08-21 Graff Jonathan M. Methods to identify signal sequences
EP1750776A2 (en) 2004-04-30 2007-02-14 Alnylam Pharmaceuticals Inc. Oligonucleotides comprising a c5-modified pyrimidine
WO2006117414A1 (es) 2005-04-29 2006-11-09 Proyecto De Biomedicina Cima, S.L. Modelo animal no humano de sarcoma
WO2008083326A2 (en) * 2006-12-29 2008-07-10 Georgetown University Targeting of ews-fli1 as anti-tumor therapy
US8232310B2 (en) 2006-12-29 2012-07-31 Georgetown University Targeting of EWS-FLI1 as anti-tumor therapy
EP2154966B1 (en) 2007-04-20 2013-08-21 The Research Foundation Of State University Of New York Benzimidazoles and pharmaceutical compositions thereof
TW201346030A (zh) 2012-04-02 2013-11-16 Gradalis Inc 依汶氏(EWING’S)肉瘤雙功能shRNA設計
EP2836481B1 (en) 2012-04-12 2018-12-26 Georgetown University Compounds and compositions for treating ewings sarcoma family of tumors
JP6389884B2 (ja) * 2013-10-24 2018-09-12 ジョージタウン・ユニバーシティGeorgetown University 癌を治療するための方法及び組成物

Also Published As

Publication number Publication date
WO2015061229A1 (en) 2015-04-30
US20160263086A1 (en) 2016-09-15
KR20160065986A (ko) 2016-06-09
CA2927148A1 (en) 2015-04-30
EP3060207A1 (en) 2016-08-31
US20170157089A1 (en) 2017-06-08
MX2016004678A (es) 2017-03-10
US9511050B2 (en) 2016-12-06
EP3060207A4 (en) 2017-04-12
JP2016534084A (ja) 2016-11-04
CN105848654A (zh) 2016-08-10
CN105848654B (zh) 2018-10-02
RU2016114498A3 (OSRAM) 2018-08-13
RU2016114498A (ru) 2017-11-29
AU2014340398A1 (en) 2016-06-09
JP6389884B2 (ja) 2018-09-12

Similar Documents

Publication Publication Date Title
IL273090B (en) Methods and preparations for the treatment of cancer
IL281058A (en) Compositions and methods for treating anemia
IL245281A0 (en) Methods and preparations for the treatment of cancer
SMT201700595T1 (it) Composizioni e metodi per trattare il cancro
SG11201510751YA (en) Composition and vaccine for treating prostate cancer
EP3077049A4 (en) Compositions and methods for treating vitiligo
IL239921A0 (en) Preparations containing solutions in solid state and their use for the treatment of pain
IL244353A0 (en) Compounds and use for cancer treatment
SG11201508878WA (en) Methods of treating cancer
EP3004395A4 (en) Compositions and methods for treating cancer
EP3052102A4 (en) Compositions and methods for treating cancers
ZA201506330B (en) Methods and compositions for treating leukemia
SG11201510300RA (en) Compositions and methods for treating skin
HUE048625T2 (hu) Módszer rák kezelésére
SG10201703977UA (en) Methods of treating cancer
EP2984185A4 (en) Methods and compositions for treating cancer
WO2014160368A9 (en) Compositions and methods for treating cancer
EP2841102A4 (en) METHOD AND COMPOSITIONS FOR THE TREATMENT OF CANCER